Barclays
SXTP icon

Barclays’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Barclays’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25K Buy
1,856
+1,478
+391% +$4.2K ﹤0.01% 4814
2025
Q4 		$769 Buy
+378
New +$1.75K ﹤0.01% 5086

Other funds holding SXTP

KCM
Kathmere Capital Management Wayne, Pennsylvania $1.62B AUM 17.7% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
TPWA
Twin Peaks Wealth Advisors Burlingame, California $397M AUM 23.23% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Barclays's SXTP Position: Q1 2026 in Review

Barclays increased its 60 Degrees Pharmaceuticals (SXTP) stake by 391% in Q1 2026, buying an estimated $4.2K and bringing the position to 1,856 shares worth $3.25K. The position accounts for ﹤0.01% of the portfolio, ranked #4814.

Barclays first reported a position in SXTP in Q4 2025 and has held it in 2 quarters since. 8 funds tracked by Wall St. Rank hold SXTP as of Q1 2026.

  • Barclays held 1,856 shares of 60 Degrees Pharmaceuticals worth $3.25K as of Q1 2026.
  • Barclays bought 1,478 60 Degrees Pharmaceuticals shares in Q1 2026, an estimated $4.2K.
  • 60 Degrees Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4814 holding.
  • Barclays first reported a position in 60 Degrees Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 8 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.